论文部分内容阅读
目的:探讨细胞周期蛋白CyclinD1、促凋亡基因Bax及多药耐药基因MDR1在非小细胞肺癌(NSCLC)中的表达及生物学特性。方法:用鼠抗人CyclinD1、鼠抗人MDR1及鼠抗人Bax单克隆抗体(mAb)对56例石蜡包埋的原发性NSCLC组织进行免疫组化染色,并与20例肺良性病变作对照,对其表达情况进行检测分析。结果:CyclinD1表达为恶性病变高于良性病变(P<0.05),与P-TNM分期及分化程度无关。Bax蛋白在NSCLC和肺良性病变中表达无明显差异性,但在NSCLC中,肿块≥3cm时其表达高于肿块<3cm,有淋巴结转移者高于无淋巴结转移者,Ⅲ~Ⅳ期高于I~Ⅱ期,中~高分化高于低~中分化(各组P<0.05)。MDR1在NSCLC中的表达高于肺良性病变(P<0.05),并且在肿块≥3cm高于肿块<3cm(P<0.05),有淋巴结转移高于无淋巴结转移(P<0.05)。结论:CyclinD1的过表达与肺癌的发生有关:Bax在NSCLC发生的早期低表达,而在中晚期高表达,说明Bax在早期的抑制有诱癌形成的可能,晚期则加速癌细胞凋亡,参与机体的抗癌机制;MDR1的过表达与NSCLC的发展与预后有关,并有利于NSCLC耐药的监测与评价。
Objective: To investigate the expression and biological characteristics of CyclinD1, Bax and multidrug resistance gene MDR1 in non-small cell lung cancer (NSCLC). Methods: 56 cases of paraffin-embedded primary NSCLC tissues were immunohistochemically stained with mouse anti-human CyclinD1, mouse anti-human MDR1 and mouse anti-human Bax monoclonal antibody (mAb), and compared with 20 cases of benign lung disease , The expression of its detection analysis. Results: The expression of CyclinD1 in malignant lesions was higher than that in benign lesions (P <0.05), which was not related to the stage and differentiation of P-TNM. Bax protein expression in NSCLC and benign lung disease was no significant difference, but in NSCLC, mass ≥ 3cm when the expression was higher than the mass <3cm, with lymph node metastasis was higher than those without lymph node metastasis, Ⅲ ~ Ⅳ higher than the I ~ Â ... ¡, â ... ¢ high differentiation was higher than the low ~ moderate differentiation (each group P <0.05). The expression of MDR1 in NSCLC was higher than that in benign lung (P <0.05), and was higher than that of tumor <3cm (P <0.05), and higher in lymph node metastasis than in non-lymph node metastasis (P <0.05). Conclusion: The overexpression of CyclinD1 is associated with the development of lung cancer. The low expression of Bax in early stage of NSCLC and the high expression in middle stage and late stage indicate that Bax can inhibit the induction of cancer formation in the early stage and accelerate the apoptosis of cancer cells in the late stage. The anti-cancer mechanism of the body; MDR1 overexpression and NSCLC development and prognosis, and is conducive to the monitoring and evaluation of drug resistance in NSCLC.